moxifloxacin has been researched along with rabeprazole in 10 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (rabeprazole) | Trials (rabeprazole) | Recent Studies (post-2010) (rabeprazole) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,073 | 446 | 405 |
| Protein | Taxonomy | moxifloxacin (IC50) | rabeprazole (IC50) |
|---|---|---|---|
| Adenosine receptor A3 | Homo sapiens (human) | 3.219 | |
| Urease subunit alpha | Helicobacter pylori 26695 | 0.29 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.219 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.737 | |
| D(3) dopamine receptor | Homo sapiens (human) | 2.326 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.219 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 0.49 | |
| Urease subunit beta | Helicobacter pylori 26695 | 0.29 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 0.49 | |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | 3.25 | |
| Cytosolic endo-beta-N-acetylglucosaminidase | Homo sapiens (human) | 4.47 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 8.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, Y; Chung, KH; Hwang, JH; Jeong, SH; Jin, E; Kim, JW; Kim, N; Lee, DH; Seo, JY; Shin, CM | 1 |
| Hwang, JJ; Kim, N; Lee, AR; Lee, DH; Park, YS; Shin, CM; Yoon, H | 2 |
| Hwang, JJ; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
1 review(s) available for moxifloxacin and rabeprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for moxifloxacin and rabeprazole
| Article | Year |
|---|---|
Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Multivariate Analysis; Odds Ratio; Pilot Projects; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Stomach Diseases; Time Factors; Treatment Outcome | 2015 |
Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Time Factors; Treatment Outcome | 2015 |
7 other study(ies) available for moxifloxacin and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Rabeprazole; Republic of Korea; Retrospective Studies; Salvage Therapy; Stomach; Tetracycline; Treatment Failure; Treatment Outcome; Urea | 2014 |
Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2015 |
Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Breath Tests; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retreatment; Retrospective Studies; Time Factors; Treatment Failure | 2015 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Failure; Treatment Outcome | 2017 |